• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Axsome Therapeutics Inc.

    6/17/25 4:01:01 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AXSM alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001934008
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Axsome Therapeutics, Inc.
    SEC File Number
    001-37635
    Address of Issuer
    ONE WORLD TRADE CENTER, 29TH FLOOR
    NEW YORK
    NEW YORK
    10007
    Phone
    (212) 332-3241
    Name of Person for Whose Account the Securities are To Be Sold
    Murdock Hunter R.
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Charles Schwab & Co., Inc.
    3000 Schwab Way
    Westlake � TX � 76262
    7500751975.004923636506/17/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common06/17/2025Employee Stock Option ExerciseAxsome Therapeutics, Inc.Checkbox not checked750006/17/2025Broker Payment for Cashless Exercise

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Hunter R. Murdock
    ONE WORLD TRADE CENTER, 29TH FLOOR
    NEW YORK � NY � 10007
    Axsome Therapeutics, Inc.06/16/20257500768154.00

    144: Remarks and Signature

    Remarks
    Date of Notice
    06/17/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    03/04/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Hunter R. Murdock

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $AXSM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AXSM

    DatePrice TargetRatingAnalyst
    7/3/2025$190.00Overweight
    Morgan Stanley
    6/3/2025$185.00Outperform
    Oppenheimer
    4/7/2025$200.00Buy
    Jefferies
    2/11/2025$176.00Buy
    Deutsche Bank
    12/31/2024$124.00 → $122.00Outperform
    Mizuho
    9/3/2024$140.00Overweight
    Wells Fargo
    8/6/2024$95.00 → $106.00Neutral → Buy
    BofA Securities
    7/22/2024$130.00Buy
    Needham
    More analyst ratings

    $AXSM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for AUVELITY issued to AXSOME THERAPEUTICS, INC.

      Submission status for AXSOME THERAPEUTICS, INC.'s drug AUVELITY (ORIG-1) with active ingredient DEXTROMETHORPHAN HYDROBROMIDE AND BUPROPION HYDROCHLORIDE has changed to 'Approval' on 08/18/2022. Application Category: NDA, Application Number: 215430, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

      8/19/22 12:36:14 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXSM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley resumed coverage on Axsome Therapeutics with a new price target

      Morgan Stanley resumed coverage of Axsome Therapeutics with a rating of Overweight and set a new price target of $190.00

      7/3/25 7:49:15 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Axsome Therapeutics with a new price target

      Oppenheimer initiated coverage of Axsome Therapeutics with a rating of Outperform and set a new price target of $185.00

      6/3/25 7:47:30 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Axsome Therapeutics with a new price target

      Jefferies initiated coverage of Axsome Therapeutics with a rating of Buy and set a new price target of $200.00

      4/7/25 8:43:21 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXSM
    Leadership Updates

    Live Leadership Updates

    See more
    • Axsome Therapeutics, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; December 7, 2023 deadline.

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 28, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Axsome Therapeutics, Inc. ("Axsome" or "the Company") (NASDAQ:AXSM) investors that a lawsuit filed on behalf of investors that purchased Axsome securities between May 10, 2021 and April 22, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options fo

      11/28/23 6:51:20 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors

      NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Susan Mahony, PhD, has been appointed to Axsome's board of directors, effective immediately. Dr. Mahony most recently served on the board of directors of Horizon Therapeutics from 2019 until its acquisition by Amgen in October 2023. She was formerly Senior Vice President of Eli Lilly and Company and President of Lilly Oncology, where under her leadership, the business unit evolved from one to five marketed medicines. At Lilly, she held leadership position

      10/11/23 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXSM
    Financials

    Live finance-specific insights

    See more
    • Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4

      NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the second quarter of 2025 on Monday, August 4, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic) or +1 (201) 389-0851 (international). A live webcast of the conference call can be accessed on the "Webcasts & Presentat

      7/9/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

      Total 1Q 2025 net product revenue of $121.5 million, representing 62% year-over-year growth AUVELITY® 1Q 2025 net product sales of $96.2 million, representing 80% year-over-year growth SUNOSI® 1Q 2025 net product revenue of $25.2 million, representing 17% year-over-year growth SYMBRAVO® approved for the acute treatment of migraine; commercial launch on track for June 2025 NDA for AXS-14 for the management of fibromyalgia submitted to the FDA Supplemental NDA submission for AXS-05 in Alzheimer's disease agitation on track for 3Q 2025 NDA submission for AXS-12 for cataplexy in patients with narcolepsy anticipated in 2H 2025 Positive topline results of FOCUS Phase 3 trial of solriamfetol

      5/5/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5

      NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the first quarter of 2025 on Monday, May 5, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic) or +1 (201) 389-0851 (international). A live webcast of the conference call can be accessed on the "Webcasts & Presentation

      4/8/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXSM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4

      NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the second quarter of 2025 on Monday, August 4, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic) or +1 (201) 389-0851 (international). A live webcast of the conference call can be accessed on the "Webcasts & Presentat

      7/9/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21

      NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will host its Frontiers in Brain Health R&D Day on July 21, 2025, starting at 11:00 a.m. Eastern Time in New York City. The event will highlight Axsome's singular, innovative late-stage CNS pipeline. At the event, physician key opinion leaders will discuss the company's current indications in neurology and psychiatry. Members of the Axsome management team will provide an overview of the clinical development programs. The presenters will be available to answer questions at the e

      7/7/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month

      NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today is joining with the Alzheimer's disease advocacy community to raise awareness of the growing impact of Alzheimer's disease in the United States and the importance of brain health during this year's Alzheimer's & Brain Awareness Month. "Alzheimer's & Brain Awareness Month offers the perfect opportunity for all Americans to take charge of their brain health," said Sarah Fried, Vice President of Corporate Initiatives at the Alzheimer's Association. "For the first time ever there are now more than 7

      6/20/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXSM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

      SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)

      2/14/24 3:46:49 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

      SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)

      2/14/24 7:26:39 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

      SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)

      2/13/24 4:58:57 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXSM
    SEC Filings

    See more
    • SEC Form 144 filed by Axsome Therapeutics Inc.

      144 - Axsome Therapeutics, Inc. (0001579428) (Subject)

      6/17/25 4:01:01 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Axsome Therapeutics, Inc. (0001579428) (Filer)

      6/10/25 7:24:12 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Axsome Therapeutics, Inc. (0001579428) (Filer)

      6/9/25 4:30:53 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXSM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • General Counsel Murdock Hunter R. exercised 13,514 shares at a strike of $29.91 and sold $1,370,647 worth of shares (13,514 units at $101.42) (SEC Form 4)

      4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

      6/23/25 7:42:47 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel Murdock Hunter R. exercised 22,500 shares at a strike of $29.91 and sold $2,276,850 worth of shares (22,500 units at $101.19) (SEC Form 4)

      4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

      6/18/25 9:16:04 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Coleman Mark

      4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

      6/10/25 7:00:20 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care